European urology最新文献

{"title":"Congress Calendar","authors":"","doi":"10.1016/j.eururo.2025.09.4136","DOIUrl":"10.1016/j.eururo.2025.09.4136","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"88 5","pages":"Pages e103-e104"},"PeriodicalIF":25.2,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145247915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Stephen J. Freedland, John P. Mulhall, Martin Gleave, et al. Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study. Eur Urol 2025;87:507–11","authors":"Xianghu Meng, Yibo Hua, Rijin Song","doi":"10.1016/j.eururo.2025.07.035","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.07.035","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"24 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145247483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic and Transcriptomic Profiling of High-risk Bladder Cancer Reveals Diverse Molecular and Microenvironment Ecosystems","authors":"Khyati Meghani, Yanni Yu, Noah Frydenlund, Erik Z. Li, Bonnie Choy, Sarki A. Abdulkadir, Joshua J. Meeks","doi":"10.1016/j.eururo.2025.09.4138","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.4138","url":null,"abstract":"<h3>Background and objective</h3>High-risk bladder cancer recurs in 30% of cases and causes fatal outcomes in 10% within 2 yr despite surgical resection, endoscopic surveillance, and bacillus Calmette-Guérin (BCG) immunotherapy. The global shortage of BCG highlights the urgent need for alternative or complementary strategies. This study aimed to identify molecular subtypes and develop a precision framework to predict recurrence risk and guide treatment.<h3>Methods</h3>Transcriptomic profiling and targeted genomic sequencing were performed with validation by single-cell RNA sequencing and spatial transcriptomics. A machine learning model incorporating genomic and transcriptomic features was developed to predict recurrence risk.<h3>Key findings and limitations</h3>Four subtypes were identified, and an inflamed tumor subtype with high endogenous retroelement expression and increased commensal bacterial presence demonstrated the highest responsiveness to BCG therapy. The predictive model achieved high accuracy (area under the curve = 0.87, 95% confidence interval: 0.72–1.0) for recurrence risk. Findings are limited by sample size, necessitating validation in larger cohorts.<h3>Conclusions and clinical implications</h3>We describe a new conceptual framework for T1 tumors. Those with increased immune cells (subtype 2) have a better response to BCG, which may be secondary to enhanced baseline immune activity.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"31 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Francesco Montorsi, Paolo Zauirto, and Giorgio Gandaglia’s Letter to the Editor re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study. Eur Urol 2025;88:167–75","authors":"Cameron Englman, Francesco Giganti, Caroline M. Moore","doi":"10.1016/j.eururo.2025.09.4153","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.4153","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"59 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and International Evaluation of an Artificial Intelligence–based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non–muscle-invasive Bladder Cancer","authors":"Jethro C.C. Kwong, Zizo Al-Daqqaq, Yashan Chelliahpillai, Soomin Lee, Kellie Kim, Maximiliano Ringa, Andrew Feifer, Katherine Lajkosz, Marian S. Wettstein, Amy Chan, Taeweon Lee, Myky Nguyen, Wassim Kassouf, Peter C. Black, Rodney H. Breau, Michele Lodde, Adrian Fairey, Jean-Baptiste Lattouf, Claudio Jeldres, Ricardo Rendon, Girish S. Kulkarni","doi":"10.1016/j.eururo.2025.09.4145","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.4145","url":null,"abstract":"<h3>Background and objective</h3>Current non–muscle-invasive bladder cancer (NMIBC) tools perform suboptimally in predicting progression risk to potentially lethal muscle-invasive disease. We aimed to improve risk assessment using artificial intelligence approaches (PROGression Risk assessment in NMIBC [PROGRxN-BCa]).<h3>Methods</h3>PROGRxN-BCa was trained using 14 clinicopathological features on 3324 NMIBC patients treated from 2005 to 2022 at four Canadian institutions. External testing was performed on 9335 patients treated from 2005 to 2023 across 30 North American and European institutions. The primary outcome was time to progression (muscle-invasive or metastatic disease). PROGRxN-BCa was compared with the European Association of Urology (EAU) risk calculator. Performance was characterised using concordance index (c-index), calibration plots, instability assessments, decision curve analysis, and an algorithmic audit.<h3>Key findings and limitations</h3>During a median follow-up of 3.3 yr (interquartile range 1.6–5.8), 1405 of 12659 patients progressed. In the external testing cohort, PROGRxN-BCa had significantly higher c-index (0.79, 95% confidence interval [CI] 0.77–0.80) and net benefit overall and across different subgroups compared with the EAU risk calculator (0.71, 95% CI 0.70–0.73, <em>p</em> &lt; 0.001). This improvement was consistent regardless of treatment with bacillus Calmette-Guérin, adherence to guideline-concordant care, and World Health Organization 1973 or 2004/2022 grading system, and was consistent among patients with at least 5 yr of follow-up. It also outperformed other guideline-endorsed tools and a previously published artificial intelligence model. Compared with guideline recommendations, PROGRxN-BCa improved substratification of intermediate-risk patients into distinct risk tertiles, with estimated 5-yr progression risks of 2%, 7%, and 15%—the latter in line with high-risk NMIBC.<h3>Conclusions and clinical implications</h3>PROGRxN-BCa outperformed current tools in the largest NMIBC cohort of its kind. Its integration into guidelines could improve risk stratification and patient management.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"107 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Radiation-induced Cystitis Treated with Hyperbaric Oxygen Therapy (RICH-ART): Long term follow-up of a Randomised Controlled, Phase 2–3 Trial","authors":"Emilien Seizilles de Mazancourt, Paul Meria","doi":"10.1016/j.eururo.2025.09.4155","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.4155","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"8 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Da-Ming Xu and Hui Han’s Letter to the Editor re: Aldo Brassetti, Alfredo Maria Bove, Flavia Proietti, et al. Single-port Antegrade Robotic Lymphadenectomy: A Novel Minimally Invasive Approach to Treat Lymph Nodes in Men with Penile Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.06.016","authors":"Aldo Brassetti, Alfredo Bove, Flavia Proietti, Giuseppe Simone","doi":"10.1016/j.eururo.2025.09.4150","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.4150","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"28 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study","authors":"Siamak Daneshmand, Renata Zaucha, James W.F. Catto, Ben Tran, Viraj Master, Yair Lotan, Geraldine Pignot, Andrea Tubaro, Nobuaki Shimizu, Nikhil Vasdev, Eugene K. Lee, Giuseppe Procopio, Fernando Galanternik, Lauren Crow, Kris Deprince, Vahid Naini, Spyros Triantos, Mahadi Baig, Wei Zhu, Jodi K. Maranchie","doi":"10.1016/j.eururo.2025.09.4152","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.4152","url":null,"abstract":"<h3>Background and objective</h3>High-risk (HR) or intermediate-risk (IR) non–muscle-invasive bladder cancer (NMIBC) carries a high probability of recurrence and/or progression. We present the final analysis results of erdafitinib in HR- or IR-NMIBC with fibroblast growth factor receptor 3/2 alterations (<em>FGFR3/2</em>alt) from the phase 2 THOR-2 study.<h3>Methods</h3>Cohort 1 (HR-NMIBC papillary only) with prior bacillus Calmette-Guérin was randomized 2:1 to erdafitinib or intravesical chemotherapy. Cohorts 2 (carcinoma in situ ± papillary) and 3 (IR-NMIBC) received erdafitinib. The primary endpoint was recurrence-free survival (RFS) for cohort 1. Exploratory endpoints included complete response (CR) rate and duration of response (DoR) for cohorts 2 and 3.<h3>Key findings and limitations</h3>In cohort 1 (<em>n</em> = 73), median RFS was not reached (NR) for erdafitinib (95% confidence interval [CI] 28.6 mo–not estimable [NE]) and 11.6 mo (95% CI 5.3–NE) for intravesical chemotherapy (hazard ratio 0.28 [95% CI 0.13–0.61; nominal <em>p</em> = 0.0007]; median follow-up, 18.5 and 16.6 mo, respectively). In cohort 2 (<em>n</em> = 16), CR rates were 94% (95% CI 70–100%) and 81% (95% CI 54–96%) at 8 and 32 wk, respectively; the median DoR (mDoR) was 23.3 mo (95% CI 10.0–NE; <em>n</em> = 15). In cohort 3 (<em>n</em> = 18), the CR rate was 89% (95% CI 65–99%) and mDoR was NR (95% CI 13.4 mo–NE). Most common treatment-related adverse event in pooled erdafitinib cohorts (<em>N</em> = 83) was hyperphosphatemia (76%). Limitations include early termination in cohort 1 and small sample size that precluded prespecified hypothesis testing.<h3>Conclusions and clinical implications</h3>Oral erdafitinib demonstrated high efficacy in <em>FGFR3/2</em>alt HR-/IR-NMIBC, with a manageable safety profile.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"16 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Matthew J. Roberts, Giorgio Gandaglia, Daniela E. Oprea-Lager, et al. Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications. Eur Urol 2025;87:619–21","authors":"Andrew J. Vickers, Karim Touijer","doi":"10.1016/j.eururo.2025.08.032","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.08.032","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"65 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145241459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Semen Quality and Lifespan: A Study of 78 284 Men Followed for up to 50 Years","authors":"Walter D. Cardona Maya, Temidayo S. Omolaoye, Stefan S. du Plessis","doi":"10.1016/j.eururo.2025.09.4157","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.09.4157","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"11 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145229310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}